Ainos (AIMD) AI Stock Analysis

• Market Cap: $17.79M
• Dividend Yield: N/A
• Average Volume (3M): 4.79M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.15
• Revenue Growth: 70.25%
• EPS Growth: 66.22%
• Country: US
• Employees: 44
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): -0.99
• Shares Outstanding: 4,657,861
• 10 Day Avg. Volume: 14,230,118
• 30 Day Avg. Volume: 4,792,976
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.21
• Enterprise Value/Revenue: 201.89
• Enterprise Value/Gross Profit: 345.11
• Enterprise Value/Ebitda: -1.83
• 1Y Price Target: $3.50
• Price Target Upside: -8.38% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 51 Neutral
• Price Target: $3.50 ▼(-8.38% Downside)

Ainos' overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. However, positive corporate events and technical indicators provide some optimism for future growth.

Ainos Business Overview & Revenue Model

Company Description

Ainos (AIMD) is a biotechnology company focused on developing innovative medical diagnostic solutions. The company specializes in point-of-care testing and is particularly known for its advanced breath analysis technology, which aids in the early detection and management of various medical conditions, including respiratory diseases and other metabolic disorders. Ainos operates within the healthcare sector, providing valuable diagnostic tools that enhance patient care and streamline clinical workflows.

How the Company Makes Money

Ainos generates revenue primarily through the sales of its diagnostic devices and related consumables. The company’s revenue model includes direct sales to healthcare providers, hospitals, and diagnostic laboratories. Additionally, Ainos may engage in strategic partnerships with other healthcare firms or research institutions to expand its market reach and enhance product development. These collaborations can lead to co-development agreements, licensing deals, and joint marketing efforts, contributing significantly to the company's overall earnings.

Ainos Financial Statement Overview

Summary

Ainos is facing severe financial challenges, with a complete decline in revenue and persistent losses. The balance sheet reflects high leverage and limited financial stability, while cash flow analysis reveals significant operational inefficiencies and liquidity constraints. These factors indicate a precarious financial position.

Income Statement

Ainos has experienced a severe decline in revenue over the years, with Total Revenue dropping to zero in the most recent year. This, coupled with negative gross and net profit margins, indicates significant operational challenges and profitability issues. There is also a lack of revenue growth, as recent results reflect a substantial decrease from previous years.

Balance Sheet

Ainos has a high debt-to-equity ratio, indicating leveraged financial structure, but the equity position has improved from negative to positive over time. However, the equity ratio remains relatively low, reflecting limited financial stability. Return on Equity is negative due to ongoing losses, suggesting inefficiencies in generating returns on shareholder investment.

Cash Flow

The company's cash flow metrics reveal persistent negative operating and free cash flows, highlighting liquidity challenges. Despite some improvements in financing activities, operating cash flow remains significantly negative compared to net income, indicating operational inefficiencies and cash flow constraints.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.73K	122.11K	3.52M	594.56K	16.56K
Gross Profit	-31.87K	-253.73K	1.41M	410.38K	5.29K
EBITDA	-9.44M	-8.77M	-9.14M	-1.84M	-1.43M
Net Income	-14.86M	-13.77M	-14.01M	-3.89M	-1.45M
Balance Sheet
Total Assets	28.82M	31.84M	37.11M	40.82M	260.29K
Cash, Cash Equivalents and Short-Term Investments	3.89M	1.89M	1.85M	1.75M	22.25K
Total Debt	12.00M	5.96M	1.27M	3.62M	953.00K
Total Liabilities	13.30M	7.39M	2.48M	30.63M	1.10M
Stockholders Equity	15.52M	24.45M	34.63M	10.20M	-838.28K
Cash Flow
Free Cash Flow	-5.83M	-4.79M	-3.66M	-1.39M	-506.79K
Operating Cash Flow	-5.81M	-4.69M	-3.02M	-1.25M	-499.55K
Investing Cash Flow	-125.29K	-101.53K	-630.18K	-180.52K	-7.24K
Financing Cash Flow	8.03M	4.92M	3.83M	3.15M	120.00K

Ainos Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.82
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIMD, the sentiment is Positive. The current price of 3.82 is above the 20-day moving average (MA) of 2.85, above the 50-day MA of 2.85, and above the 200-day MA of 2.75, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 71.82 is Negative, neither overbought nor oversold. The STOCH value of 54.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AIMD.

Ainos Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	66 Neutral	S$1.54B	6.97	9.48%	5.03%	18.81%	21.25%
KPRX	56 Neutral	$8.69M	4.67	-43.39%	―	-100.00%	49.47%
AIMD	51 Neutral	$17.79M	―	-97.80%	―	70.25%	66.22%
EVAX	50 Neutral	$4.01M	―	-205.75%	―	2552.29%	60.70%
IBIO	42 Neutral	$11.00M	―	-90.83%	―	650.00%	85.42%
APRE	40 Underperform	$9.84M	―	-67.54%	―	-34.07%	23.79%
ACXP	39 Underperform	$7.03M	―	-285.93%	―	―	53.79%

Ainos Corporate Events

Ainos Secures $2.1M Order with ASE Technology

On August 6, 2025, Ainos, Inc. announced a $2.1 million order with ASE Technology Holding Co., Ltd. for deploying its AI Nose in semiconductor manufacturing. This marks the first revenue-generating milestone for AI Nose in industrial applications, following its initial success in the senior care sector. The deployment of 1,400 AI Nose units across ASEH’s sites in Taiwan is part of Ainos’ strategy to convert strategic partnerships into active deployments, enhancing smart manufacturing through AI-powered scent intelligence. This agreement strengthens Ainos’ position in Asia’s advanced manufacturing base and reinforces its role as a pioneer in the emerging field of SmellTech.

Ainos Regains Nasdaq Compliance, Eyes AI Expansion

On July 16, 2025, Ainos, Inc. announced that it has regained compliance with the Nasdaq Capital Market’s minimum bid price requirement, marking a significant milestone for the company. This achievement coincides with Ainos’ strategic efforts to expand its AI Nose platform, which includes partnerships with major companies like ASE Technology Holding and Kenmec, and aims for large-scale commercialization by 2026. The company has outlined a 90-day roadmap to enhance its market presence, focusing on deploying AI Nose units, showcasing integrated technology at industry events, and pursuing new partnerships in Asia and Europe.

Ainos Partners with Kenmec for AI Integration

On June 24, 2025, Ainos, Inc. announced a strategic partnership with Kenmec Mechanical Engineering Co., Ltd., a leader in automation and system integration. This collaboration aims to integrate Ainos’ AI Nose and smell language model technologies into Kenmec’s smart factory ecosystem, enhancing environmental awareness and anomaly detection in unmanned environments. This partnership marks a significant step in Ainos’ international expansion, following successful implementations in Japan’s eldercare and semiconductor sectors. By combining AI Nose with Kenmec’s platforms, the partnership seeks to redefine industrial perception and capitalize on the growing demand for intelligent environmental sensing.